- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01788254
Open Label Study for the Functional Characterization of Drug Metabolism and Transport (IKP243)
Aim of this study is to comprehensively assess in healthy volunteers the metabolic processes and factors that define drug response. Sources of variability are to be investigated and factors that can alter the hepatic metabolism and the pharmacokinetics of drugs shall be quantified.
Determination of variability is important when the pharmacokinetics of new drugs is being investigated and when the concept of individualized medicine is to be further developed. It is important to identify and differentiate between pharmaceutical, physiological (e.g. liver blood flow, renal function), environmental (e.g. foods and lifestyle), and genetic sources of inter-individual variability. For instance, inaccurate or false conclusions may be drawn from a single pharmacokinetic study, if the investigated medicine is metabolized by an enzyme with large inter-individual variability. Knowing the causes of variability and of the quantitative contribution of various processes might help to improve the oral formulations of drugs, might help selecting the right preclinical tests and selection criteria during clinical development, provide the basis to understand the influence of disease and to optimize established drug treatments in order to make future drug treatment safer and more efficient.
This study is designed as an add-on to the study "TWINS: Open Label Repeated Dose Study for the Evaluation of Heritability of and Genetic Influences on Drug Pharmacokinetics" (Eudra-CT: 2008-006223-31). Twins are not a random sample of the population, and they differ in their developmental environment. In this sense they are not representative for the population Thus, the results of TWINS cannot be automatically generalized but instead require validation in a representative population sample. While both studies assess pharmacologic factors important for drug response, TWINS contributes in particular data on the heritability of these processes.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Stuttgart, Germany, 70376
- Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology
-
Tübingen, Germany, 72076
- Abteilung Klinische Pharmakologie
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written informed consent obtained prior to study entry including informed consent for genetic research
- Both genders (male and female)
- Healthy adults aged ≥18 to <65 years
- Bodyweight not less than 48 kg and not more than 120 kg. BMI not less than 18 kg/m² and not greater than 33 kg/m².
- Smokers and nonsmokers. Smoking siblings will only be included if both siblings are smoking to a similar extend (+/- 10 cigarettes per day)
- healthy volunteers
- Dizygotic twins will only be included if both siblings are of the same gender, either male or female and triplets, quadruplets or other multiplets if at least two siblings of the same gender are considered.
Exclusion Criteria:
- Participation in a clinical trial involving the administration of medicines during the last 30 days or use of any other investigational or non-registered drug or vaccine during the study period or within 30 days preceding the first dose of study drugs
- Blood, plasma or thrombocyte donation during the last 30 days prior to application of the test drugs.
- Pregnancy or lactation period
- Any relevant clinical and pathological findings at physical examination, ECG, taking blood pressure or in clinical chemistry tests (deviation of more than 10% of the normal range).
- Positive signal from urinary drug test
- Raynaud's syndrome
- Taking any medication within 7 days before or during the trial with the following exceptions: Single doses of mild analgesics (e.g. aspirin, paracetamol, ibuprofen) an oral contraceptives.
- History of severe hypersensitivity reactions and anaphylaxis.
- History of intolerance or allergic reactions to or contraindication for any of the investigational products.
- Clinically significant diseases as judged by the investigator.
- Contraindication against MRI.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Drug cocktail
A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
|
A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Blood levels and clearance (dose/AUC) of midazolam
Time Frame: 8 hours
|
8 hours
|
Blood levels and clearance (dose/AUC) of torsemide
Time Frame: 8h
|
8h
|
Blood levels and clearance (dose/AUC) of codeine
Time Frame: 8h
|
8h
|
Blood levels and clearance (dose/AUC) of talinolol
Time Frame: 8h
|
8h
|
Blood levels and clearance (dose/AUC) of pravastatin
Time Frame: 8h
|
8h
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
determine metabolite profile
Time Frame: 8 hours
|
To determine metabolite profile of the phenotyping probes and to assess Pharmacokinetic parameters and/or metabolic ratios in relation to underlying genotypes as well as to validate the heritability estimates derived from TWINS.
|
8 hours
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Matthias Schwab, Prof., M.D., Dr. Margarete Fischer Bosch Institute of Clinical Pharmacology and University of Tuebingen
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Adrenergic beta-Antagonists
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Antihypertensive Agents
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Antimetabolites
- Natriuretic Agents
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Analgesics, Opioid
- Narcotics
- Tranquilizing Agents
- Psychotropic Drugs
- Membrane Transport Modulators
- Hypnotics and Sedatives
- Adjuvants, Anesthesia
- Anti-Anxiety Agents
- GABA Modulators
- GABA Agents
- Diuretics
- Respiratory System Agents
- Antitussive Agents
- Sodium Potassium Chloride Symporter Inhibitors
- Midazolam
- Pravastatin
- Codeine
- Talinolol
- Torsemide
Other Study ID Numbers
- IKP243
- 2011-002291-16 (EUDRACT_NUMBER)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Genotype-related Drug Metabolism
-
California Pacific Medical Center Research InstituteChildren's Mercy Hospital Kansas CityWithdrawnMethamphetamine Metabolism, CYP2D6 GenotypeUnited States
-
Mayo ClinicNot yet recruitingSide Effect of Drug | Pharmacogenomic Drug Interaction | Drug Metabolism, Poor, CYP2D6-Related | Ineffective Drug Action | Drug Metabolism, Poor, CYP2C19-RelatedUnited States
-
Companion Dx Reference Lab, LLCUnknownGenetics of Drug MetabolismUnited States
-
Renaissance RXSyntactxUnknown
-
General Genetics CorporationSyntactxUnknownGenetics of Drug MetabolismUnited States, Puerto Rico
-
Seoul National University HospitalCompletedInfluence of Genotype of Drug Metabolizing Enzyme or Transporter on the Pharmacokinetics/Pharmacodynamics of Clopidogrel | Influence of Aspirin on the Pharmacokinetics/Pharmacodynamics of ClopidogrelKorea, Republic of
-
Indiana UniversityNational Institute of General Medical Sciences (NIGMS)CompletedAdverse Effect of Drug Therapy Metabolism Medications (Diagnosis)United States
-
Lawson Health Research InstituteCompletedCytochrome P450 2D6 Ultra-rapid MetabolismCanada
-
Beth Israel Deaconess Medical CenterNational Center for Research Resources (NCRR); Harvard UniversityCompletedAcetaminophen Poisoning | Acetaminophen Metabolism | Drug Metabolism by ExcipientsUnited States
-
Genelex CorporationUniversity of UtahCompletedDrug Interaction Potentiation | Adverse Drug Events | Adverse Drug Reactions | Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant | Drug Metabolism, Poor, CYP2D6-RELATED | Drug Metabolism, Poor, CYP2C19-RELATED | Cytochrome P450 Enzyme Deficiency | Cytochrome P450 CYP2D6 Enzyme Deficiency | Cytochrome... and other conditionsUnited States
Clinical Trials on Codeine
-
University of ZimbabweUZ-CHS-PERFECTSuspendedImpacted Third Molar Tooth | PAINZimbabwe
-
Children's Hospitals and Clinics of MinnesotaCompletedPain | TonsillitisUnited States
-
University of Southern DenmarkCompletedMetformin | Organic Cation Transporter 1 | CodeineDenmark
-
Mayo ClinicWyeth is now a wholly owned subsidiary of PfizerCompletedGastric Motility DisorderUnited States
-
Roxane LaboratoriesCompleted
-
Roxane LaboratoriesCompleted
-
Aziende Chimiche Riunite Angelini Francesco S.p.ACross Research S.A.Completed
-
Universitaire Ziekenhuizen KU LeuvenCompleted